Eli Lilly's retatrutide delivers 28.3% weight loss across 3 indications

Eli Lilly's triple agonist retatrutide drove 28.3 percent weight loss at 80 weeks and improved three additional conditions, the company said June 6.

"Retatrutide's potential to treat obesity and its related complications represents a significant advance," a Lilly spokesperson said.

The Phase 3 TRIUMPH-1 study enrolled patients with obesity without diabetes, showing 28.3 percent weight reduction over 80 weeks — comparable to bariatric surgery, Lilly said. In TRIUMPH-4, patients with obesity or overweight and knee osteoarthritis saw 26.6 percent placebo-adjusted weight loss at 68 weeks. The TRANSCEND-T2D-1 study evaluated the drug in type 2 diabetes patients, with A1C improvements alongside weight reduction. A dysesthesia signal emerged in more than 20 percent of patients on the 20-mg dose in TRIUMPH-4, with rates rising by dose level in TRIUMPH-1.

The multi-indication data expands retatrutide's addressable market beyond obesity into osteoarthritis and sleep apnea, conditions affecting tens of millions of patients. IQVIA forecasts obesity medicine sales reaching $92 billion in 2026 and as much as $200 billion by 2027.

Lilly has deemed retatrutide part of a "different drug category" compared with its current weight-loss drugs Zepbound and Foundayo, according to William Blair analyst Andy Hsieh. The drug activates GLP-1, GIP, and glucagon receptors simultaneously, a mechanism designed to deliver greater efficacy than dual agonists.

The company is positioning retatrutide as a next-generation treatment that could compete with Novo Nordisk's CagriSema, a fixed-dose combination of semaglutide and cagrilintide expected to hit the U.S. market early next year. Novo's CagriSema showed 23 percent weight loss at 84 weeks in a head-to-head study against Lilly's Zepbound, which achieved 25.5 percent.

Retatrutide's safety profile will be a key focus for regulators. The dysesthesia signal — an abnormal sensation described as unpleasant or painful — affected more than a fifth of patients on the highest dose in TRIUMPH-4. Lilly has not disclosed whether it plans to address the signal through dose titration or patient selection.

The data positions retatrutide as a potential best-in-class obesity treatment with multiple label expansions. Investors will watch for Lilly's regulatory filing timeline and any dose optimization strategy to address the dysesthesia signal.

This article is for informational purposes only and does not constitute investment advice.